



***Transforming Everyday Life
into Extraordinary Ideas***



Canadian Longitudinal Study on Aging: Advancing the Science of Population Health and Aging through Interdisciplinary Research

Parminder Raina, PhD

Canada Research Chair in GeroScience

Raymond and Margaret Labarge Chair in Optimal Aging

Professor, Department of Clinical Epidemiology and


Biostatistics, Faculty of Health Sciences,

McMaster University, Hamilton

Vancouver, April 2012

Population aging

- Due to declining fertility and increasing longevity (demographic transition)
- Unprecedented, accelerating, shifts will be permanent
- Profound implications for human life, including health




Population Totals in Canada by Age Group and Year

AGE	MALES	BOTH SEXES	FEMALES
80+	229898	670192	440294
75-79	255599	622194	366595
70-74	364298	833991	469693
65-69	497996	1084588	586592
60-64	578596	1190087	611491
55-59	618096	1238387	620291
50-54	673295	1339986	666691
45-49	844194	1674182	829988
40-44	1076892	2138777	1061885
35-39	1173491	2344675	1171184
30-34	1311991	2597873	1285882
25-29	1282190	2528572	1246382
20-24	1067593	2108978	1041385
15-19	984993	1925780	940787
10-14	980292	1912979	932687
5-9	998293	1953079	954786
0-4	1000393	1953280	952887
1991 TOTALS	13938100	28117600	14179500

Rectangularization of the survival curve

FURTHER INCREASE IN LIFE EXPECTANCY

Squaring the survival curve



JAMES F. FRIES, M.D., THE NEW ENGLAND JOURNAL OF MEDICINE, JULY 17, 1980,

Compression of morbidity




Figure: Mortality According to Age in the Absence of Premature Death


- Morbidity compressed into a short period prior to death
- Represented an important shift in thinking
- Departure from the medical model of aging, which assumed that death always occurred as a result of a disease process, and that older age was a period of inevitable decline

Compression of morbidity

Fries' paradigm based on the premise that:

- The length of human life is fixed
AND
- Chronic disease can be postponed
- Predicted that the increase in life expectancy would plateau in the coming decades, particularly life expectancy from age 65 which excludes early life mortality

Distribution of life table deaths



Evidence suggests otherwise

■ Is average life expectancy approaching an upper limit to life expectancy?

- the evidence that the average life span is 85 years is unconvincing
- there is no evidence for further rectangularization of survival curves

■ Will age at first infirmity increase?

- there is no evidence for over-all declines in incidence of morbidity: on the contrary
- evidence for actual “(de)compression” of morbidity is ambiguous


Historical increases of life expectancy

Oepen and Vaupel, Science 2002; C Finch adaptation

Phase 1
early urban

Phase 2
sanitation-nutrition

Phase 3?
regeneration
modern medicine
Social Policy Innovation




Demographic Futures

- Upward trend in life expectancy continue, cease, or reverse?
 - Effective interventions against age-related diseases
 - Improved environment for ageing
 - Life-cycle deceleration (delayed reproduction)

 - Adverse effects of excess nutrition
 - Adverse effects of alcohol and drug abuse
 - Adverse effects of increasingly sedentary lifestyles
 - Life-cycle acceleration (early maturation)

Why aging occurs



How aging is caused

Genes Associated With Avoiding Late-Life Disease in Humans

Table 4

GENE	BIOCHEMICAL FUNCTION	COMMENTS	REFERENCES
APOE	Lipoprotein metabolism	E2 variant is frequent in centenarians while E4 variant as a risk factor for Alzheimer's disease is rare in centenarians.	Schachter et al. 1994
ACE	Angiotensin-converting enzyme	Plays a role in regulating blood pressure.	Schachter et al. 1994
PAI1	Plasminogen activator inhibitor 1	Plays a role in blood clotting, thus affecting risk of stroke and heart attack.	Mannucci et al. 1997
HLA-DR	Histocompatibility locus antigen	DR variant is frequent in centenarians; resists infection and inflammation?	Ivanova et al. 1998
WRN	Possesses both DNA helicase and exonuclease activity	Gene responsible for Werner's Syndrome; mutation leads to a variety of aging-related pathologies, e.g., cataracts, cancer, osteoporosis, slow wound healing, etc.	Yu et al. 1996 Huang et al. 1998 Martin and Oshima 2000
B3AR	B-3 adrenergic receptor	Allelic form present affects time of onset of Type 2 diabetes.	Walston et al. 1995
MTHFR	5-, 10-methylenetetrahydrofolate reductase	Deficiency leads to increased levels of homocysteine and DNA hypomethylation; increases risk of cardiovascular disease and cancer.	Heijmans et al. 2000
KLOTHO	Membrane protein with β -glucosidase activity?	Homozygous variant form is underrepresented in elderly individuals.	Arking et al. 2002

Genetic Heritability of Human Lifespan

Cournil & Kirkwood *Trends in Genetics* 2001

Twin Studies

■ McGue et al (1993)		0.22
■ Herskind et al (1996)	0.25	
■ Ljungquist et al (1998)		<0.33

Traditional Family Studies



■ Philippe (1978)		0-0.24
■ Bocquet-Appel & Jakobi (1990)		0.10-0.30
■ Mayer (1990)	0.10-0.33	
■ Gavrilova et al (1998)	0.18-0.58	
■ Cournil et al (2000)		0.27

Genes account for 25% of what determines disease and longevity



Canadian Longitudinal Study on Aging
Étude longitudinale canadienne sur le vieillissement

Epigenetics



DNA AND CHROMOSOME LEVELS

Non-Biological/Medical Determinants of Aging?

- Nutrition
- Lifestyle
- Environment
 - Physical
 - Social
 - Economic
 - Work Place
 - Psychological
- Chance

Intrinsic and Extrinsic Factors

Environmental influences

(e.g., rural, socio-economic, exercise, nutrition)



Chronic diseases


(e.g., diabetes, cancer, dementia, arthritis, cardio)

(e.g., telomeres/oxidative stress,
psychological & cognitive abilities,
immune functions)

Aging



infections



Health Services Utilization



Genetics

Time (Longitudinal Study)



CLSA élcV
Canadian Longitudinal Study on Aging
Étude longitudinale canadienne sur le vieillissement

Strategic Partners

- Strategic initiative of the Canadian Institutes of Health Research (CIHR)
- Funded by CIHR and the Canada Foundation for Innovation (CFI)
- Provinces and universities across Canada



Our Vision

A research platform – infrastructure to enable state-of-the-art, interdisciplinary population-based *research* and *evidenced-based* decision-making that will lead to better health and quality of life for Canadians.




Our Aim

To study aging as a dynamic process and the inter-relationship among intrinsic and extrinsic factors from mid-life to older age.





Innovation - Cell to Society




- ▶ Mid life to old age
- ▶ Quantitative traits
 - ▶ Physical
 - ▶ Social
 - ▶ Psychological
- ▶ Gene-environment interactions
- ▶ Disease, disability, psychosocial consequences
- ▶ Adaptation



Canadian Longitudinal Study on Aging
Étude longitudinale canadienne sur le vieillissement

Interdisciplinary Research Agenda



Overall Goals of the CLSA

- The progression of **health** from middle-age to early old age to older old age
- The determinants of **well-being and quality of life**
- Risk factors (including genetics) of **chronic diseases**
 - ✓ **Cardiovascular, Cerebrovascular, Neurological, Respiratory, Vision and Hearing, Diabetes, Renal, Metabolic, Cancer, Osteoarthritis, Osteoporosis, Depression, Musculoskeletal, Cancer**
- **Cognitive functioning and mental health**
- **Disability** and the compression of morbidity
- The examination of socioeconomic and health **inequalities** in an aging population
- **Social participation, social relationships and caregiving** in an aging population
- **Retirement and post-retirement** labour market activity

Depth and Breadth of CLSA

PHYSICAL & COGNITIVE MEASUREMENTS

- Height & weight
- Waist and hip measurements
- Bioimpedence
- Arterial pressure
- Mean heart rate
- Grip strength, timed up-and-go, chair raise, 4-m walk
- Standing balance
- Vision
- Hearing
- Spirometry
- Bone density
- Aortic calcification
- ECG
- Carotid intima-media thickness
- Cognitive assessment

HEALTH INFORMATION

- Chronic disease symptoms (11 chronic conditions)
- Medication intake & compliance
- Women's health
- Self-reported health service use
- Oral health
- Preventative health
- Administrative data linkage health services & drugs
- Other administrative databases

PSYCHOSOCIAL

- Social participation
- Social networks and support
- Caregiving and care receiving
- Mood, psychological distress
- Coping, adaptation
- Work-to-retirement transitions
- Job-demand/effort reward
- Retirement planning
- Social inequalities
- Mobility-lifespace
- Built environments
- Wealth


LIFESTYLE & SOCIODEMOGRAPHIC

- Smoking
- Alcohol consumption
- Physical activity
- Nutrition
- Birth location
- Ethnicity/race/gender
- Marital status
- Education
- Income




Canadian Longitudinal Study on Aging
Étude longitudinale canadienne sur le vieillissement

Equipment and Infrastructure Supporting Research on Aging



CLSA Data Collection




Achievements

- Set up of CATI
- Successful DCS set up and pilot studies
- Infrastructure / IT Design
- Coordinated purchasing process
- Software development
- Coordinated REB process
- Partnership MOH/Data Stewards




Participant Recruitment




Canadian Longitudinal Study on Aging
Étude longitudinale canadienne sur le vieillissement

Tracking Cohort Timeline (2009-2015)



* MC= Maintaining Contact

Comprehensive Cohort Timeline (2009-2015)




*MC = Maintaining Contact

Launch of the CLSA

- First selection of 20,000 started in late 2008 in collaboration with Statistics Canada CCHS Healthy Aging module (Tracking cohort)
 - ✓ Approximately 12,500 have agreed to release their names to CLSA (5,000 have been recruited)
- Remaining 15,000 for Tracking cohort are currently being recruited; to be completed late 2012
 - ✓ Provincial Client Registries or Random Digit Dialing
- Recruitment for remaining 30,000 started in early 2012 (Comprehensive cohort); to be completed early 2015
 - ✓ Provincial Client Registries or Random Digit Dialing



Diabetes Algorithm



*If self-report is removed, then this box = 'possible diabetes'

Example

Physical Function
Mobility

Mobility

«activity & participation» *

Examples of precursors

Individual (or intrinsic)

- Chronic diseases (eg osteoarthritis)
- Neuropsychological conditions
- Cognition/Perceived health
- Medication use/Pain/ Dizziness
- Poor vision
- Fear of falling/

- Obesity/Nutrition/weight loss/appetite

- Physical activity/fitness/strength

- Functional performance (measured & reported)

- Alcohol use

- Biomarkers (inflammation, hormonal, metabolism, genetics, epigenetics)

- Personality

Contextual (or extrinsic or environmental)

- Social participation

- Transportation resources

- Community/neighbourhood characteristics

- Social network/support

Examples of consequences

Diseases

- Osteoporosis, sarcopenia

Physical Health

- Injuries/Frailty/Disability

- Poor nutrition status

Psychological Health

- Psychological distress

- Quality of life

- Loneliness

- Unmet needs

Social Health

- Social participation/engagement/capital

- Work Transitions

- Unmet needs

- Institutionalization



Canadian Longitudinal Study on Aging
Étude longitudinale canadienne sur le vieillissement

Mobility

Mobility as a precursor:

Is mobility in mid- and later life associated with physical, psychological and social functioning?
Specifically:

- How do changes in mobility impact upon indicators of psychological health including, depression, psychological distress, satisfaction with life, adjusting for other factors?

Mobility

Mobility as a mediator:

How does mobility in mid- and later life mediate relationships between determinants of health and health outcomes? Specifically:

- How does compromised mobility mediate the relationship between income and health?

Mobility

Mobility as an outcome:

How do physical, psychological, and social functioning in mid- and later life relate to changes in mobility?

Specifically:

- What is the relationship between inflammatory biomarkers (e.g., IL-6, C reactive protein, albumin), hormonal biomarkers (e.g., IGF-1, T3, T4), metabolic (e.g., fasting glucose, cholesterol) or immunological markers (TNF α), oxidative stress (e.g. vitamin E and C), vitamin D, and (Epi) genetic markers (e.g., IGF-I and Apo-E) and changes in mobility and how is this relationship is modified by SES?
- What is the relationship between neighbourhood deprivation and incident mobility disability in aging population?

Data Collection Sites (DCS)


11 ACROSS CANADA

- § 5 participants per day (40 weeks)
- § 50 mL blood
- § Urine sample
- § Hematology tests (AcT DIFF, Beckman Coulter)



Storage System


Tubes



- § 500-µL V bottom, screw- top tubes (Matrix Tubes, Thermo Fisher Scientific)
- § Open-bottomed boxes for fast scanning
- § Standard 96 well format
- § Potential for 'pick and place' robotic retrieval and storage box compression ('defragging')


Microwell Plates

- § 3-section GenPlates (Genvault) with FTA paper
- § Standard 96 well format
- § Dried overnight in GenVault FastDryer and sealed with an adhesive foilcover



Bio specimens

42 aliquots per participant



Shipping

Matrix boxes

- § Pre-charged vapor shippers (-160°C)
- § Weekly shipments to BBC (overnight courier)
- § Equipped with data loggers



GenPlates

- § Envelopes with dessicant

Quality

Standard protocols to minimize process variation

Supplies

- § Received by the BBC and packaged for monthly shipments to the DCS
- § Barcode labels for supplies generated at BBC
- § Lot numbers and expiry dates tracked centrally

Biospecimens

- § Scanned at each stage of processing and handling to provide a detailed history of the biospecimen
- § Characteristics of samples documented
- § Sample integrity maximized
 - Maximum time from collection to storage is 2 h
 - Storage at -160°C

Biorepository and Bioanalysis Centre (BBC)

HAMILTON

Biorepository

- § 31 nitrogen tanks (5 million aliquots)
- § Autofilled from a bulk nitrogen tank
- § Cryocarts
- § Personal Archive, dry storage at room temperature (humidity controlled)
- § LIMS (LabWare)
- § CryoMORE, (Air Liquide) safety monitoring system



FUTURE


ASKION C-line®
work bench



Biorepository and Bioanalysis Centre (BBC)

Biorepository

- Installation May 2012
- LIMS implementation April
- Hiring BBC coordinator




CLSA by the numbers

- 50,000 participants
 - 20 years to complete the study
 - 57,487 Lines of code making up Sabretooth, Beartooth and Mastodon (software)
 - Up to 140,000 Telephone interviews
 - Up to 210,000 Home interviews
 - Up to 210,000 Visits to data collection sites
 - Up to 8,820,000 biospecimen aliquots
 - Up to 300,000 Follow-up calls
 - Up to 129 million Questions asked during telephone interviews
 - Up to 219 million Data points collected during CLSA home interviews and visits to data collection sites
 - Up to 348 million Anticipated number of data points
- that will form the CLSA research platform



CLSA Governance Structure



Canadian Investment

\$50M Canadian investment in national platform

- \$23.5M CIHR for 5 Years (86% of the required funding)
 - ✓ Expectation is to identify non-CIHR partners (in kind or \$\$)
- \$10M CFI for 5 Years (infrastructure)
- \$10M Provinces for 5 Years (infrastructure)
- \$6.5 M Universities and other partners

CLSA Partners

- PHAC Neurological Diseases
- PHAC Injury
- Veterans Affairs
- Statistics Canada
- Ontario Ministry of Health and Long-Term Care
- Provinces
- Universities
- Large number of in-kind contributions from vendors and suppliers

COLLABORATE AND INNOVATE

INFRASTRUCTURE

- State-of-the-art facilities: bio-repository and bio-analysis laboratories, fully equipped data collection facilities and call centres across Canada, statistical analysis centre, genetics and epigenetics centre
- Novel open-source software for conducting multicentre research
- Novel hardware design and architecture
- Secure data management systems to preserve participant confidentiality
- Collaboration and harmonization with other national and international cohorts

RESEARCH

- Progression and management of disease and disability
- Risk factor identification
- Co-morbidity
- Psychosocial aspects of health
- Genetic and epigenetic aspects of disease and disability
- Biospecimen and preservation research
- Biomarker discovery for early detection and management of disease
- Research platform for auxiliary studies
- Trajectories of healthy aging
- Quality of life

OUTPUTS

- Healthcare utilization patterns
- Evidence to inform health and public policy
- Personalized medicine to improve outcomes
- Development of interventions and programs
- Development of services and products
- Research capacity
- Advanced science of aging
- Improved health of Canadians



Discussion Points

- Value of the CLSA platform
- Data access and IP policies
- Opportunities for collaboration for the core data collection CLSA
- Opportunities for analyses of the data and biological samples
- Opportunities for using CLSA facilities for non-CLSA research
- Opportunities for sub-studies

CLSA CORE TEAM

Lead PI	Parminder Raina (McMaster)
CO-PI	Christina Wolfson (McGill) and Susan Kirkland (Dalhousie)
Key Senior Co-Investigators	Gerry Mugford (Memorial), Helene Payette (Sherbrooke), Ron Postuma (McGill), Larry Chambers and Vanessa Taler (Ottawa), Harry Shannon, Cynthia Balion, Christopher Patterson, Lauren Griffith and Mark Oremus (McMaster), Mary Thompson and Chang Bo (Waterloo), Margaret Penning, Holly Tuokko, (Victoria), Verena Menec (Manitoba), David Hogan (Calgary) , Max Cynader, Michael Hayden and Michael Kobor (UBC) and Andrew Wister (SFU)
Scientific Working Group	See our website – www.clsa-elcv.ca



raina@mcmaster.ca

CLSA funded by the Government of Canada through CIHR and CFI, and provincial governments and universities

www.clsa-elcv.ca





www.clsa-elcv.ca

